All practice questions

4736 questions

Question 4021Question →

For the following adult patients receiving end-of-life care, identify the most appropriate targeted pharmacologic therapy to manage their acute distressing symptoms.

Click a left item, then click its matching right item

Items

An 82-year-old gentleman with severe idiopathic pulmonary fibrosis on maximal inhaler therapy and continuous supplemental oxygen who continues to experience agonizing breathlessness at rest.
A 69-year-old woman in the active phase of dying from glioblastoma who is unconscious and producing loud, gurgling respiratory noises that are deeply distressing to her spouse.
A 58-year-old man with metastatic cholangiocarcinoma and newly oliguric acute kidney injury who develops diffuse myoclonus and severe allodynia while receiving high-dose intravenous hydromorphone.
A 75-year-old man with end-stage liver disease receiving home hospice care who begins striking at caregivers and screaming about intruders, completely refractory to environmental redirection.

Matches

Show answer & explanation

Answer

The clinical scenarios are correctly paired with their specific symptom-directed therapies: the patient with dyspnea requires a systemic opioid, the patient with terminal secretions requires a muscarinic antagonist, the patient with opioid neurotoxicity and acute kidney injury requires opioid rotation, and the patient with agitated terminal delirium requires an antipsychotic.
Each clinical scenario presents a classic end-of-life symptom requiring a targeted pharmacologic intervention. Dyspnea is best managed with opioids to reduce the perception of breathlessness. Terminal secretions respond to anticholinergics that decrease fluid production. Opioid neurotoxicity in renal failure necessitates rotation to an opioid metabolized safely, like fentanyl. Severe agitated delirium is treated with antipsychotics when non-pharmacological interventions fail.

Step-by-Step Solution

1
Evaluate the 82-year-old patient with refractory dyspnea.
Recognize that opioids are the gold standard for treating dyspnea at the end of life.
Opioids decrease the central respiratory drive and alleviate the sensation of air hunger.
2
Assess the 69-year-old patient with loud, gurgling respiratory noises.
Identify this as terminal secretions ('death rattle').
These secretions require anticholinergic drying agents, as suctioning is often ineffective and distressing.
3
Analyze the 58-year-old patient with myoclonus, allodynia, and acute kidney injury on hydromorphone.
Diagnose opioid-induced neurotoxicity due to metabolite accumulation.
Renal failure prevents the clearance of neurotoxic metabolites; the patient must be rotated to a renally safe opioid like fentanyl.
4
Evaluate the 75-year-old patient with hyperactive, aggressive behavior.
Diagnose terminal agitated delirium.
When non-pharmacologic measures fail, antipsychotics are required to manage severe agitation and ensure safety.

Key Concept

Pharmacologic management of terminal symptoms (dyspnea, secretions, delirium, opioid neurotoxicity) in end-of-life care
Question 4022Question →

A 61-year-old man is evaluated in the intensive care unit. He was admitted 14 days ago for severe necrotizing pancreatitis. On hospital day 8, he developed a deep venous thrombosis and was started on an unfractionated heparin infusion. Three days later, his platelet count dropped from 240,000/mm3240,000/\text{mm}^3 to 85,000/mm385,000/\text{mm}^3. A serotonin release assay was positive, confirming heparin-induced thrombocytopenia (HIT). All heparin products were discontinued, and a continuous intravenous infusion of argatroban was initiated.

The patient's clinical condition has since stabilized. Three days ago, oral warfarin was initiated for long-term anticoagulation. Today, his platelet count has recovered to 175,000/mm3175,000/\text{mm}^3.

Laboratory TestResult
Prothrombin time (PT)28 seconds
International normalized ratio (INR)2.7
Activated partial thromboplastin time (aPTT)68 seconds

The target INR for this patient's long-term management is 2.0 to 3.0.

Which of the following are appropriate steps in the ongoing monitoring and therapeutic evaluation for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Continue the argatroban infusion alongside warfarin until the combined INR exceeds 4.0; Measure a chromogenic factor Xa level to assess the isolated anticoagulant effect of warfarin

Answer

The correct steps are to continue the argatroban infusion alongside warfarin until the combined INR exceeds 4.0, AND to measure a chromogenic factor Xa level to assess the isolated anticoagulant effect of warfarin.
The correct answers address the pharmacokinetic artifact caused by direct thrombin inhibitors. Because argatroban falsely elevates the INR, patients transitioning to warfarin must remain on co-therapy until the combined INR is at least >4.0. Only then should argatroban be paused for 4 to 6 hours to check a true, isolated warfarin INR. Alternatively, clinicians can circumvent the INR artifact entirely by ordering a chromogenic factor Xa level. This assay measures the depletion of Factor X (dependent on vitamin K antagonism) and does not rely on thrombin generation, making it highly accurate for monitoring warfarin in the presence of argatroban.

Step-by-Step Solution

1
Identify the patient's current clinical state
The patient is in the subacute phase of heparin-induced thrombocytopenia (HIT) with platelet recovery, currently transitioning from argatroban to warfarin.
Establishing the phase of HIT is essential, as transition to oral vitamin K antagonists (VKA) can only safely occur once platelets recover above 150,000/mm^3.
2
Interpret the laboratory findings in the context of the current medications
The INR of 2.7 is artificially elevated. Argatroban is a direct thrombin inhibitor (DTI) that falsely prolongs the prothrombin time (PT) and INR.
Failing to account for the DTI-induced INR artifact will lead to premature discontinuation of parenteral anticoagulation and severe thrombotic complications.
3
Determine the appropriate monitoring protocol for argatroban-to-warfarin transition
Guidelines dictate continuing both drugs until the combined INR is > 4.0, or using an alternative monitoring assay like chromogenic factor Xa.
When combined INR > 4.0, argatroban is stopped for 4-6 hours, and the INR is rechecked to ensure it remains therapeutic (2.0-3.0) on warfarin alone. Chromogenic factor Xa assays bypass the thrombin pathway and isolate warfarin's effect.

Key Concept

Monitoring the transition from argatroban to warfarin in heparin-induced thrombocytopenia requires accounting for the artificial INR elevation caused by direct thrombin inhibitors.
Question 4023Question →

During morning rounds on the medical ward, the care team discusses the transition plan for a 68-year-old woman. She has been hospitalized for two weeks after presenting with severe sepsis from a perforated diverticulum. Her initial course required an emergent exploratory laparotomy, colostomy creation, and a 10-day intensive care unit stay complicated by acute respiratory distress syndrome that required mechanical ventilation.

She was extubated three days ago and transferred to the floor. Her vital signs are temperature 37.1°C (98.8°F), blood pressure 124/78 mmHg, pulse 80/min, and respirations 16/min. She is breathing comfortably on room air. The surgical incision is healing appropriately, and the colostomy is functioning well.

A physical therapy assessment reveals profound generalized muscle weakness consistent with critical illness polyneuropathy. The patient requires maximum physical assistance from two staff members to transfer from the bed to a chair and cannot bear weight independently. Despite being highly motivated to recover, she becomes visibly exhausted after 30 to 45 minutes of combined physical and occupational therapy. Prior to admission, she lived at home with her husband, who suffers from advanced heart failure and relies on a wheelchair.

What is the most appropriate disposition for this patient?

Show answer & explanation

Answer: Transfer to a skilled nursing facility

Answer

Transfer to a skilled nursing facility
The correct disposition is a skilled nursing facility (SNF). This patient is medically stable following a severe illness but suffers from critical illness polyneuropathy. She requires daily skilled nursing and physical therapy to regain her functional independence. An SNF provides subacute rehabilitation for patients who need daily therapy but lack the stamina to endure the 3 hours of intensive daily therapy mandated by inpatient rehabilitation facilities (IRFs). Because she maxes out at 45 minutes of therapy and requires maximum assistance for transfers that her husband cannot provide, an SNF is the safest and most appropriate environment for her ongoing recovery.

Step-by-Step Solution

1
Evaluate the patient's current medical stability and need for ongoing acute medical care.
The patient is extubated, afebrile, and hemodynamically stable with healing wounds.
Determines whether the patient requires a long-term acute care hospital (LTACH) versus a post-acute rehabilitation setting.
2
Assess the patient's functional status and rehabilitation capacity.
The patient has severe weakness and can only tolerate 30 to 45 minutes of therapy before exhaustion.
Differentiates between the need for an inpatient rehabilitation facility (which requires tolerating 3 hours/day) and a skilled nursing facility.
3
Analyze the patient's social support and home environment.
The patient lives with a husband who is wheelchair-bound and unable to assist with transfers.
Determines if discharge home with home health services is safe and feasible.

Key Concept

Patients who require inpatient rehabilitation but cannot tolerate the 3 hours of daily therapy required for an inpatient rehabilitation facility (IRF) should be transferred to a skilled nursing facility (SNF).
Question 4024Question →

A 5454-year-old male is evaluated on hospital day 44 for altered mental status. He was originally admitted for severe alcohol withdrawal complicated by generalized tonic-clonic seizures. The patient was successfully stabilized with intravenous lorazepam followed by a loading dose of phenytoin, and he is currently receiving an oral phenytoin maintenance regimen. His medical history is significant for severe alcohol use disorder and decompensated cirrhosis. Today, the nursing staff notes that the patient is increasingly confused, lethargic, and dysarthric. When attempting to walk to the bathroom, he exhibited a wide-based, unsteady gait. Vital signs are within normal limits. Neurologic examination reveals prominent bilateral horizontal nystagmus. Asterixis is absent. Laboratory studies show the following:

Laboratory TestResultReference Range
Albumin1.9 g/dL1.9\text{ g/dL}3.5−5.0 g/dL3.5-5.0\text{ g/dL}
Total bilirubin3.5 mg/dL3.5\text{ mg/dL}0.1−1.2 mg/dL0.1-1.2\text{ mg/dL}
Ammonia35 \mumol/L35\text{ \mu mol/L}15−45 \mumol/L15-45\text{ \mu mol/L}
Total serum phenytoin11 mg/L11\text{ mg/L}10−20 mg/L10-20\text{ mg/L}

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Measure serum free phenytoin concentration

Answer

The most appropriate next step is to measure the serum free phenytoin concentration to accurately assess for drug toxicity in the setting of severe hypoalbuminemia.
This patient presents with classic manifestations of phenytoin toxicity, including altered mental status, horizontal nystagmus, dysarthria, and ataxia. While his total serum phenytoin level of 11 mg/L11\text{ mg/L} appears to be within the normal therapeutic range (10−20 mg/L10-20\text{ mg/L}), this value is deceiving due to his underlying severe cirrhosis and resulting hypoalbuminemia. Phenytoin is approximately 90%90\% bound to plasma proteins, primarily albumin. In disease states characterized by low albumin (e.g., decompensated cirrhosis, nephrotic syndrome, severe malnutrition), the fraction of unbound, active phenytoin increases significantly. The standard laboratory test for phenytoin measures the total concentration (bound plus unbound). Therefore, a seemingly normal total phenytoin level in a patient with an albumin of 1.9 g/dL1.9\text{ g/dL} represents a massive increase in the free, pharmacologically active drug crossing the blood-brain barrier. The most appropriate next step in treatment evaluation is to order a serum free phenytoin concentration, which provides an accurate assessment of the drug's true systemic exposure and confirms the diagnosis of toxicity.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient exhibits confusion, dysarthria, ataxia, and horizontal nystagmus.
These findings are classic, hallmark signs of phenytoin toxicity.
2
Evaluate the laboratory results in the context of the medication regimen.
The total serum phenytoin level is 11 mg/L11\text{ mg/L}, which falls within the standard therapeutic range of 10−20 mg/L10-20\text{ mg/L}. However, the patient has profound hypoalbuminemia (1.9 g/dL1.9\text{ g/dL}).
Phenytoin is highly protein-bound in the serum. Evaluating the albumin level is crucial when interpreting total phenytoin levels.
3
Synthesize the pharmacokinetic principles to determine the next management step.
Because albumin is low, there are fewer binding sites for phenytoin. The absolute amount of unbound (free) phenytoin increases, penetrating the central nervous system and causing toxicity, even though the 'total' level appears normal. The next step is to measure the free phenytoin level.
Treatment evaluation and dose adjustments for highly protein-bound drugs in malnourished or cirrhotic patients must rely on the free fraction rather than the total fraction.

Key Concept

In patients with significant hypoalbuminemia, standard total serum phenytoin levels underestimate the amount of free (active) drug. Clinicians must measure free phenytoin levels or calculate an adjusted level to properly evaluate therapy and prevent severe toxicity.

Alternative Method

Instead of ordering a serum free phenytoin level, clinicians can quickly calculate the patient's estimated adjusted total phenytoin level using the Winter-Tozer equation: Adjusted Phenytoin = Measured Total Phenytoin / ((0.2 × Albumin) + 0.1). For this patient, the adjusted level would be 11 / ((0.2 × 1.9) + 0.1) = 11 / 0.48 = 22.9 mg/L. This calculated value exceeds the therapeutic upper limit of 20 mg/L, confirming clinical toxicity.
Estimated Time:2m 0s
Question 4025Question →

A 48-year-old man with advanced amyotrophic lateral sclerosis is admitted to the hospital with severe aspiration pneumonia and acute hypercapnic respiratory failure. On evaluation, he is lethargic, oriented only to person, and lacks medical decision-making capacity. The patient has a legally valid advance directive, executed two years ago while he had full capacity, which explicitly states, "I refuse intubation and mechanical ventilation under any circumstances." At that same time, he also designated his husband as his durable power of attorney for healthcare.

The patient's respiratory status worsens, and he is in impending respiratory arrest. His husband, who is at the bedside, becomes highly distressed and tells the physician, "I know what his living will says, but I cannot lose him today. I am his designated proxy, and I demand that you intubate him to save his life."

Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Withhold intubation, as the explicit written directive takes precedence over the proxy's demand

Answer

The most appropriate action is to withhold intubation, as the explicit written directive takes precedence over the proxy's demand.
The correct action is to withhold intubation, as the patient's explicit written directive takes precedence. When an incapacitated patient has a clear, applicable, and legally valid advance directive (living will), it functions as a direct extension of their autonomy. A designated healthcare proxy is ethically and legally bound by the 'substituted judgment' doctrine, meaning they must make decisions aligned with the patient's known wishes. A proxy cannot unilaterally override a patient's clear written refusal of life-sustaining treatment based on their own emotional distress or personal preferences.

Step-by-Step Solution

1
Assess the patient's clinical status and decision-making capacity.
The patient is lethargic, confused, and lacks capacity to make current medical decisions.
To determine whether the patient can direct his own care or if an advance directive/surrogate must be utilized.
2
Identify available advance directives and authorized decision-makers.
The patient has a clear living will refusing intubation and a legally designated healthcare proxy (his husband).
To establish the legal framework for subsequent medical interventions.
3
Resolve the conflict between the living will and the proxy's current demands.
The living will is followed, and intubation is withheld despite the husband's requests.
A designated proxy is bound by the substituted judgment doctrine and cannot override the patient's explicit, written autonomous choice.

Key Concept

A legally valid, explicit advance directive (living will) representing an incapacitated patient's autonomous choice supersedes the contradictory demands of a designated healthcare proxy.
Estimated Time:1m 0s
Question 4026Question →

During a routine executive briefing, the chief medical officer highlights a concerning trend of patients leaving the emergency department without being evaluated by a physician. To systematically tackle this throughput failure, the clinical operations committee adopts the Lean Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) framework. Arrange the following committee actions in the correct chronological sequence according to this methodology.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence strictly follows the DMAIC framework: Define (project charter), Measure (baseline data), Analyze (process maps and charts), Improve (pilot protocol), and Control (monitoring dashboard).
The DMAIC methodology is a structured, data-driven quality strategy essential for improving processes in healthcare. The mandatory chronological sequence is Define, Measure, Analyze, Improve, and Control. Adhering to this specific sequence ensures that solutions are based on objective data and root cause analysis rather than assumptions, and that improvements are sustained over time.

Step-by-Step Solution

1
Identify the 'Define' phase.
Developing a project charter establishes the scope and goal, placing it first.
Quality improvement projects must begin by clearly defining the problem and objectives.
2
Identify the 'Measure' phase.
Gathering baseline metrics quantifies the current state, placing it second.
Current performance must be measured objectively before it can be analyzed or changed.
3
Identify the 'Analyze' phase.
Constructing process maps and Pareto charts identifies root causes, placing it third.
Data must be analyzed to locate specific bottlenecks causing the operational issue.
4
Identify the 'Improve' phase.
Piloting a new fast-track protocol implements a solution, placing it fourth.
Targeted interventions are designed based on the analysis of root causes.
5
Identify the 'Control' phase.
Implementing a monitoring dashboard sustains the change, placing it fifth.
Long-term success requires ongoing measurement to ensure improvements are maintained.

Key Concept

Lean Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) Methodology
Question 4027Question →

A 31-year-old man with a history of treatment-resistant schizophrenia is evaluated during a routine follow-up visit. He was started on clozapine 66 weeks ago after failing trials of risperidone, aripiprazole, and haloperidol. He is currently maintained on a stable dose of 300 mg/day300 \text{ mg/day}. The patient is of Northern European descent. He reports feeling well, with a significant reduction in his auditory hallucinations, and has no fever, chills, sore throat, or malaise. His temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 122/78 mmHg122/78 \text{ mmHg}, and pulse is 82/min82/\text{min}. Routine laboratory testing reveals a total leukocyte count of 4,200/μL4,200/\mu\text{L} and an absolute neutrophil count of 1,350/μL1,350/\mu\text{L}. Prior to initiating clozapine, his absolute neutrophil count was 3,600/μL3,600/\mu\text{L}. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Continue clozapine and monitor the absolute neutrophil count three times weekly

Answer

Continue clozapine and monitor the absolute neutrophil count three times weekly.
The correct management for this patient is to continue clozapine and monitor the absolute neutrophil count (ANC) three times weekly. According to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines for patients in the general population (without benign ethnic neutropenia), an ANC between 1,000/μL1,000/\mu\text{L} and 1,499/μL1,499/\mu\text{L} constitutes mild neutropenia. In this scenario, clozapine should not be discontinued; instead, the clinician must increase the frequency of ANC monitoring to three times weekly until the ANC reaches or exceeds 1,500/μL1,500/\mu\text{L}. Treatment interruption is only required if the ANC falls below 1,000/μL1,000/\mu\text{L} (moderate neutropenia), and permanent discontinuation is mandated if the ANC drops below 500/μL500/\mu\text{L} (severe neutropenia/agranulocytosis).

Step-by-Step Solution

1
Evaluate the patient's absolute neutrophil count (ANC) against the standard reference thresholds.
The patient's ANC is 1,350/μL1,350/\mu\text{L}.
Accurate interpretation of the ANC is required to apply the Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines.
2
Determine the neutropenia severity category for a patient without Benign Ethnic Neutropenia (BEN).
An ANC between 1,000/μL1,000/\mu\text{L} and 1,499/μL1,499/\mu\text{L} is classified as mild neutropenia.
Management protocols strictly depend on the precise severity classification of neutropenia.
3
Apply the guideline-directed management for mild neutropenia.
The correct action is to continue clozapine therapy and increase ANC monitoring frequency to three times weekly.
Mild neutropenia does not warrant therapy interruption, but closer surveillance is mandated until the ANC returns to ≥1,500/μL\ge 1,500/\mu\text{L}.

Key Concept

Clozapine REMS guidelines mandate that patients with mild neutropenia (ANC 1,000−1,499/μL1,000 - 1,499/\mu\text{L}) should continue clozapine therapy but undergo increased ANC monitoring (three times weekly) until the count normalizes.
Question 4028Question →

A prospective cohort study evaluates the impact of a novel genetic marker on the development of severe coronary artery disease (CAD) over 1010 years. The incidence of CAD is 10%10\% in the exposed group (marker positive) and 2%2\% in the unexposed group (marker negative). The overall incidence of CAD in the entire study population is 3.6%3.6\%. Match each calculated epidemiological value below to its corresponding measure of association or impact.

Click a left item, then click its matching right item

Items

5.05.0
8.0%8.0\%
80.0%80.0\%
1.6%1.6\%
12.512.5

Matches

Show answer & explanation

Answer

The correct matches are: 5.0 matches Relative Risk; 8.0% matches Attributable Risk; 80.0% matches Attributable Risk Percent; 1.6% matches Population Attributable Risk; and 12.5 matches Number Needed to Harm.
Each value is mathematically derived from the fundamental incidence rates: Relative Risk is the ratio of exposed to unexposed incidence (5.05.0); Attributable Risk is the absolute difference (8.0%8.0\%); Attributable Risk Percent is the proportion of risk in the exposed due to the exposure (80.0%80.0\%); Population Attributable Risk is the difference between total population risk and unexposed risk (1.6%1.6\%); and Number Needed to Harm is the inverse of the Attributable Risk in decimal form (12.512.5).

Step-by-Step Solution

1
Extract the relevant incidence rates provided in the study scenario.
Incidence in exposed (IeI_e) = 10%10\%; Incidence in unexposed (IuI_u) = 2%2\%; Total population incidence (ItI_t) = 3.6%3.6\%.
Identifying these baseline parameters is required before applying the formulas for measures of association and impact.
2
Calculate the Relative Risk (RR) and the absolute Attributable Risk (AR).
RR=IeIu=10%2%=5.0RR = \frac{I_e}{I_u} = \frac{10\%}{2\%} = 5.0. AR=Ie−Iu=10%−2%=8.0%AR = I_e - I_u = 10\% - 2\% = 8.0\%.
RR quantifies how many times more likely the outcome is in the exposed, while AR provides the absolute excess risk.
3
Calculate the Attributable Risk Percent (ARP) for the exposed group.
ARP=Ie−IuIe=10%−2%10%=80.0%ARP = \frac{I_e - I_u}{I_e} = \frac{10\% - 2\%}{10\%} = 80.0\%.
ARP determines the fraction of the disease in the exposed group that can be specifically attributed to the genetic marker exposure.
4
Calculate the Population Attributable Risk (PAR).
PAR=It−Iu=3.6%−2.0%=1.6%PAR = I_t - I_u = 3.6\% - 2.0\% = 1.6\%.
PAR evaluates the excess disease incidence in the entire study population that is attributable to the risk factor.
5
Calculate the Number Needed to Harm (NNH).
NNH=1AR=10.08=12.5NNH = \frac{1}{AR} = \frac{1}{0.08} = 12.5.
NNH translates the absolute risk increase into a clinically intuitive metric of how many patients need to be exposed to observe one excess harmful event.

Key Concept

Measures of Association and Impact calculations
Question 4029Question →

Determine the most appropriate validated risk stratification tool used to guide the immediate care setting disposition (e.g., safe outpatient discharge versus hospital admission) for each clinical scenario. Match each patient presentation to its corresponding disposition tool.

Click a left item, then click its matching right item

Items

A 68-year-old patient evaluated in the emergency department for fever, productive cough, and a new lobar infiltrate on chest radiograph.
A 60-year-old patient evaluated in the emergency department for a single episode of melena, blood urea nitrogen of 28 mg/dL, and stable vital signs.
A 45-year-old patient evaluated in the emergency department for sudden-onset pleuritic chest pain, normal vital signs, and a positive computed tomography pulmonary angiogram.
A 50-year-old patient evaluated in the emergency department for acute, non-radiating chest discomfort, a normal electrocardiogram, and negative initial troponin.

Matches

Show answer & explanation

Answer

Community-Acquired Pneumonia matches CURB-65; Upper GI Bleeding matches Glasgow-Blatchford Score; Pulmonary Embolism matches PESI; Undifferentiated Chest Pain matches HEART Score.
Each clinical scenario corresponds to a specific acute condition where the immediate care setting disposition (outpatient vs. inpatient vs. ICU) is guided by a validated risk score. The CURB-65 score objectively evaluates community-acquired pneumonia. The Glasgow-Blatchford Score (GBS) evaluates the need for admission in upper gastrointestinal bleeding. The Pulmonary Embolism Severity Index (PESI) determines if outpatient management is safe for acute pulmonary embolism. The HEART score assesses undifferentiated chest pain to safely rule out acute coronary syndrome and avoid unnecessary hospital admissions.

Step-by-Step Solution

1
Identify the underlying primary acute clinical condition for each patient vignette.
The scenarios describe community-acquired pneumonia, upper gastrointestinal bleeding, acute pulmonary embolism, and undifferentiated chest pain.
Disposition pathways and triage decisions are protocolized based on the specific acute disease process.
2
Determine the objective, disease-specific risk stratification tool intended to evaluate severity for each condition.
Pneumonia uses CURB-65 (or PSI); Upper GI bleed uses Glasgow-Blatchford; PE uses PESI; Chest pain uses HEART.
Safe care setting transitions require moving beyond clinical gestalt to objective mortality and complication risk prediction.
3
Map the specific scoring systems to their respective patient presentations.
Match each tool to its clinical scenario based on its role in guiding the immediate transition from the emergency department to either outpatient care or hospital admission.
This establishes the appropriate disposition pathway directly addressing the patient's immediate triage needs.

Key Concept

Validated risk stratification tools objectively guide disposition and care setting transitions by predicting short-term adverse outcomes, thereby identifying which patients are safe for outpatient management and which require hospital admission.
Question 4030Question →

A 78-year-old man is evaluated for discharge planning on hospital day 12 following admission for a severe acute ischemic stroke. His hospital course was complicated by aspiration pneumonia, which has now fully resolved after a 7-day course of intravenous antibiotics. His medical history includes moderate chronic obstructive pulmonary disease (COPD) and hypertension.

Currently, the patient is hemodynamically stable and his oxygen saturation is 95% on room air. Neurological examination shows dense left-sided hemiparesis and left homonymous hemianopia. He has moderate oropharyngeal dysphagia but is safely tolerating a mechanical soft diet with thickened liquids.

Physical and occupational therapy evaluations indicate that he requires maximal assistance for bed mobility and transfers from bed to chair. He is cognitively intact, highly motivated, and actively participates in his rehabilitation sessions. However, due to dyspnea from his underlying COPD and generalized deconditioning, he experiences severe exhaustion and can only participate in 60 to 90 minutes of combined therapy per day before requiring prolonged rest.

He lives in a single-story home with his 76-year-old wife, who has severe rheumatoid arthritis and is physically unable to assist with his transfers. The patient has standard Medicare coverage and limited out-of-pocket financial resources.

Which of the following is the most appropriate discharge disposition for this patient?

Show answer & explanation

Answer: Skilled nursing facility

Answer

Skilled nursing facility
The correct disposition is a skilled nursing facility (SNF). This patient has ongoing subacute rehabilitation needs following a severe stroke, but he cannot be safely discharged home because he requires maximal assistance for transfers, which his wife cannot provide due to her severe rheumatoid arthritis. Although he is highly motivated, his severe deconditioning and COPD limit his therapy tolerance to 60-90 minutes daily. This strictly disqualifies him from an inpatient rehabilitation facility (IRF), which requires patients to tolerate and benefit from intensive rehabilitation consisting of at least 3 hours of therapy per day (or 15 hours over a 7-day period). An SNF is the appropriate level of care because it can safely manage his transfer needs and provide lower-intensity rehabilitation (typically 1-2 hours per day) covered by Medicare following a qualifying inpatient hospital stay.

Step-by-Step Solution

1
Assess the patient's medical stability.
The patient is hemodynamically stable, the pneumonia is resolved, and he no longer requires daily acute physician intervention.
Medical stability rules out the need for continued acute inpatient care or a Long-term acute care hospital (LTACH).
2
Evaluate the patient's functional needs and social support.
He requires maximal assistance for transfers, and his wife is physically unable to provide this assistance.
A lack of adequate physical support at home makes discharge to the home setting (even with intermittent home health) unsafe.
3
Determine the patient's rehabilitation tolerance and potential.
He is motivated but can only tolerate 60 to 90 minutes of combined therapy per day due to cardiopulmonary limitations.
Inpatient rehabilitation facilities (IRFs) mandate a tolerance of 3 hours of daily intensive therapy. Since he cannot meet this requirement, a skilled nursing facility (SNF) is the most appropriate setting for his subacute rehabilitation needs.

Key Concept

Patients who require post-acute rehabilitation and nursing care, but cannot tolerate the intensive 3-hour daily therapy requirement of an Inpatient Rehabilitation Facility (IRF), should be discharged to a Skilled Nursing Facility (SNF).
Question 4031Question →

A 28-year-old primigravida at 39 weeks gestation is admitted to the labor and delivery unit in active labor. She requests epidural analgesia. During preparation, a nurse nearly connects the epidural bupivacaine infusion into the patient's peripheral intravenous line due to similar-appearing tubing ports. The error is recognized and intercepted just before administration. In response to this near miss, the department director convenes a multidisciplinary quality and safety team. Rather than solely investigating this specific event, the team is tasked with mapping out the entire process of neuraxial medication administration on the unit. They brainstorm all potential ways the tubing, labeling, and administration steps could fail. The team then assigns numerical scores to each potential failure based on its severity, likelihood of occurrence, and probability of going undetected. The combined scores are used to prioritize the rollout of new, physically incompatible tubing connectors. Which of the following quality improvement methodologies is the team employing?

Show answer & explanation

Answer: Failure mode and effects analysis

Answer

Failure mode and effects analysis
The correct answer is Failure mode and effects analysis (FMEA). FMEA is a proactive, prospective quality improvement tool designed to identify potential system failures before they cause patient harm. A hallmark of FMEA is the multidisciplinary mapping of a process and the calculation of a Risk Priority Number (RPN) for every identified potential failure. The RPN is calculated by multiplying three numerical scores: the Severity of the failure, the likelihood of its Occurrence, and the likelihood that it will go Undetected. High RPNs direct where to implement strong systemic safeguards, such as forced-function physical barriers (e.g., incompatible tubing).

Step-by-Step Solution

1
Identify the trigger event and the subsequent administrative response described in the vignette.
A near miss occurred (epidural medication nearly given IV). The administration responded by convening a team to map the entire medication administration process.
Understanding the context sets up the distinction between investigating the specific event vs. evaluating the entire system.
2
Analyze the specific actions performed by the multidisciplinary team.
The team brainstorms potential failures and assigns numerical scores based on severity, likelihood, and detection probability.
These specific actions are defining characteristics of distinct quality improvement tools.
3
Match the team's actions to the correct quality improvement methodology.
Assigning scores for severity, occurrence, and detection to calculate a risk priority number is the exact definition of a Failure Mode and Effects Analysis (FMEA).
Although the process was triggered by a near miss, the methodology chosen by the team is prospective and systematic, identifying it as FMEA.

Key Concept

Failure Mode and Effects Analysis (FMEA) is a prospective, systematic quality improvement methodology used to identify, score, and prioritize potential system vulnerabilities (using a Risk Priority Number based on severity, occurrence, and detection) before they reach the patient.
Question 4032Question →

A 4242-year-old female with a history of bipolar disorder is brought to the emergency department by her family due to progressively worsening lethargy, coarse tremors, and severe ataxia over the past three days. She has been stable on lithium carbonate for five years but was recently prescribed lisinopril for hypertension by her primary care physician. Initial laboratory evaluation reveals a serum lithium concentration of 3.8 mEq/L3.8 \text{ mEq/L} and a serum creatinine of 2.4 mg/dL2.4 \text{ mg/dL} (baseline 0.9 mg/dL0.9 \text{ mg/dL}). Arrange the following therapeutic and monitoring actions in the most appropriate chronological sequence for managing this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct clinical sequence is to begin with intravenous fluid resuscitation, proceed to emergent intermittent hemodialysis, monitor lithium levels every 2 to 4 hours to detect tissue rebound, perform a repeat hemodialysis session if rebound reaches toxic levels, and finally transition to daily monitoring once stable.
Severe acute-on-chronic lithium toxicity with acute kidney injury (AKI) requires a specific sequenced treatment and monitoring protocol. Management must begin with aggressive isotonic intravenous fluids to correct volume depletion and maximize glomerular filtration. Because the patient demonstrates severe neurological symptoms and a lithium level >2.5 mEq/L>2.5 \text{ mEq/L} with AKI, emergent intermittent hemodialysis is definitively indicated to rapidly clear the toxin. Crucially, lithium has a large volume of distribution and shifts slowly from the intracellular to the intravascular space. Hemodialysis only clears the intravascular compartment; thus, once dialysis stops, lithium redistributes from tissues back into the blood. Therefore, the treatment evaluation necessitates measuring serum levels every 22 to 44 hours immediately post-dialysis to monitor for this 'rebound' effect. A second hemodialysis session is frequently required to clear this redistributed load. Finally, once levels are consistently <1.0 mEq/L<1.0 \text{ mEq/L} without further rebound, monitoring can be safely de-escalated to a daily frequency.

Step-by-Step Solution

1
Administer aggressive intravenous isotonic saline.
Corrects hypovolemia and maximizes endogenous renal clearance.
The patient's lithium retention is worsened by ACE inhibitor-induced efferent arteriolar vasodilation and volume depletion. Restoring renal perfusion is the mandatory first step while coordinating advanced therapies.
2
Initiate intermittent hemodialysis.
Rapidly extracts lithium from the intravascular compartment.
Hemodialysis is strictly indicated for lithium toxicity when serum levels exceed 2.5 mEq/L in the setting of acute kidney injury, severe neurological symptoms, or both.
3
Measure serum lithium concentrations every 2 to 4 hours post-dialysis.
Evaluates the expected post-dialysis rebound in serum lithium concentration.
Because lithium slowly moves from the intracellular to the intravascular space, a significant rebound in serum levels predictably occurs 2 to 8 hours after the termination of hemodialysis.
4
Perform a second session of hemodialysis.
Clears the redistributed intravascular lithium burden.
The rebound phenomenon often pushes serum levels back into the toxic range, requiring sequential dialysis runs to achieve definitive clearance.
5
Transition to daily serum lithium monitoring.
Confirms sustained non-toxic levels without extracorporeal assistance.
Once the rebound phase has passed and levels remain consistently sub-therapeutic or normal (<1.0 mEq/L), intensive monitoring can be safely de-escalated.

Key Concept

Management and post-dialysis rebound monitoring in severe lithium toxicity.
Question 4033Question →

A 22-year-old woman is brought to the emergency department by her roommate 2 hours after intentionally ingesting an unknown quantity of acetaminophen. She is currently asymptomatic. Her vital signs are within normal limits, and her physical examination is unremarkable. Intravenous access is established. Arrange the following steps in the most appropriate chronological order for evaluating and monitoring this patient's potential acetaminophen toxicity.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first wait until 4 hours post-ingestion to obtain a serum acetaminophen level, then plot this level on the Rumack-Matthew nomogram, initiate N-acetylcysteine if indicated, and finally monitor serial liver chemistries to determine when to discontinue therapy.
The evaluation and monitoring of acute acetaminophen toxicity follows a strict protocol to maximize diagnostic accuracy and therapeutic efficacy. Because acetaminophen requires time to be fully absorbed and distributed from the gastrointestinal tract, serum levels drawn prior to 4 hours post-ingestion are clinically uninterpretable. Therefore, the first step is to obtain a level exactly at the 4-hour mark. Once this level is obtained, it is plotted on the Rumack-Matthew nomogram, which graphs serum concentration against time since ingestion. If the coordinates fall on or above the standard treatment line, the patient is at significant risk for hepatotoxicity, and N-acetylcysteine (NAC) should be initiated. Since the antidote is nearly 100% effective at preventing liver damage if given within 8 hours of ingestion, waiting for the 4-hour level in an early-presenting patient is both safe and appropriate. Finally, the duration of NAC therapy is guided by ongoing monitoring. The infusion is continued until the patient is asymptomatic, acetaminophen levels are undetectable, liver transaminases are clearly improving, and synthetic liver function (INR) is normal.

Step-by-Step Solution

1
Obtain a serum acetaminophen level at 4 hours post-ingestion.
An interpretable serum concentration is acquired.
Acetaminophen absorption is not complete before 4 hours; levels drawn earlier cannot accurately predict toxicity.
2
Plot the level on the Rumack-Matthew nomogram.
The patient's risk of developing hepatotoxicity is stratified.
The nomogram provides an evidence-based treatment line to guide clinical decision-making.
3
Initiate N-acetylcysteine (NAC) therapy if indicated by the nomogram.
Antidote therapy is started to replenish glutathione stores.
Starting NAC within 8 hours of ingestion prevents hepatotoxicity in nearly all patients.
4
Monitor serial liver chemistries (AST/ALT) and coagulation studies (INR).
The patient's clinical trajectory and treatment response are assessed.
Resolution of hepatic injury markers dictates when it is safe to discontinue NAC therapy.

Key Concept

In acute acetaminophen ingestions presenting under 8 hours, clinicians should wait until 4 hours post-ingestion to obtain a serum level, plot it on the Rumack-Matthew nomogram to guide N-acetylcysteine initiation, and monitor serial liver chemistries to determine when to safely discontinue therapy.
Question 4034Question →

A prospective cohort study is conducted to evaluate the association between the regular use of a novel synthetic oral glucocorticoid and the development of avascular necrosis (AVN) of the femoral head. The study follows 4,0004,000 patients prescribed the new glucocorticoid and 6,0006,000 patients prescribed standard nonsteroidal anti-inflammatory drugs (NSAIDs) for similar rheumatologic conditions. Over a 1010-year follow-up period, 160160 patients in the glucocorticoid group and 6060 patients in the NSAID group develop AVN.

Based on these findings, what percentage of the AVN cases in the glucocorticoid group is theoretically attributable to the use of the new drug?

Show answer & explanation

Answer: 75

Answer

75
The correct answer is 7575. The Attributable Risk Percent (ARP) represents the fraction of disease in the exposed group that is directly attributable to the exposure. It is calculated as Incidence in exposed−Incidence in unexposedIncidence in exposed\frac{\text{Incidence in exposed} - \text{Incidence in unexposed}}{\text{Incidence in exposed}}. In this study, the incidence in the exposed (glucocorticoid) group is 160/4,000=4%160 / 4,000 = 4\%. The incidence in the unexposed (NSAID) group is 60/6,000=1%60 / 6,000 = 1\%. Therefore, ARP=4%−1%4%=3%4%=75%\text{ARP} = \frac{4\% - 1\%}{4\%} = \frac{3\%}{4\%} = 75\%. Alternatively, this can be calculated using Relative Risk (RR). RR=4%/1%=4RR = 4\% / 1\% = 4. ARP=RR−1RR=4−14=75%\text{ARP} = \frac{RR - 1}{RR} = \frac{4 - 1}{4} = 75\%.

Step-by-Step Solution

1
Calculate the incidence of the outcome in the exposed group.
Ie=1604,000=0.04I_e = \frac{160}{4,000} = 0.04 (or 4%4\%)
This establishes the total absolute risk of developing the disease when the exposure is present.
2
Calculate the incidence of the outcome in the unexposed group.
Iu=606,000=0.01I_u = \frac{60}{6,000} = 0.01 (or 1%1\%)
This establishes the baseline risk of the disease occurring without the exposure.
3
Calculate the Attributable Risk Percent (ARP).
ARP=Ie−IuIe×100%=0.04−0.010.04×100%=75%\text{ARP} = \frac{I_e - I_u}{I_e} \times 100\% = \frac{0.04 - 0.01}{0.04} \times 100\% = 75\%
This formula determines the specific proportion of cases in the exposed group that are a direct result of the exposure.

Key Concept

Attributable Risk Percent (ARP) measures the proportion of disease in an exposed group that is directly attributable to the exposure, calculated as (Ie−Iu)/Ie(I_e - I_u) / I_e or (RR−1)/RR(RR - 1) / RR.
Question 4035Question →

An 82-year-old woman is evaluated for discharge planning. She was admitted 4 days ago for an acute kidney injury secondary to poor oral intake and dehydration, which has fully resolved with intravenous fluids. During the hospitalization, the medical team notes significant cognitive deficits. A Montreal Cognitive Assessment (MoCA) score is 15/30. Her daughter, who lives in another state and cannot provide direct care, arrives and reports that the patient has recently been getting lost in her own neighborhood, forgetting to pay bills, and leaving the stove burner on unattended. The patient currently lives alone in a single-story house.

Physical and occupational therapy evaluations determine that the patient is independently ambulatory without an assistive device. She is physically capable of transferring, bathing, and dressing herself, although she requires frequent verbal cueing to initiate and complete these tasks. She takes only oral medications for hypertension and hypothyroidism. She does not require any intravenous medications, wound care, or ongoing physical therapy. Both the patient and her daughter agree that the patient can no longer safely live alone and wish to transition her to an appropriate facility.

Which of the following is the most appropriate care setting for this patient's disposition?

Show answer & explanation

Answer: Assisted living facility

Answer

Assisted living facility
The correct answer is an assisted living facility. This patient has moderate dementia with significant safety risks (wandering, leaving the stove on) and impairment in instrumental activities of daily living (IADLs), requiring 24-hour supervision and cueing. However, she is physically independent, requires only oral medications, and has no active need for daily skilled nursing care (e.g., complex wound care, intravenous medications) or skilled therapy (e.g., daily physical therapy). Assisted living facilities provide housing, meals, continuous supervision, and assistance with ADLs and IADLs, which perfectly matches her need for custodial care rather than skilled medical care.

Step-by-Step Solution

1
Evaluate the patient's physical and medical needs.
The patient is physically independent (ambulates well, physically capable of ADLs) and requires only oral medications. She has no skilled nursing or intensive therapy needs.
Determining the presence or absence of skilled needs is the first step in ruling out high-acuity facilities like a skilled nursing facility or inpatient rehabilitation facility.
2
Evaluate the patient's cognitive status and safety requirements.
The patient has significant cognitive impairment (MoCA 15/30), requires verbal cueing for ADLs, and displays unsafe behaviors at home (wandering, leaving the stove on).
Cognitive deficits often drive disposition decisions when physical needs are low, as these patients require continuous supervision to ensure safety.
3
Match the patient's combined needs to the appropriate post-acute care setting.
An assisted living facility (or memory care unit) provides the necessary 24-hour supervision, safety monitoring, and assistance with IADLs/ADLs without requiring a skilled medical justification.
Appropriate resource utilization ensures patient safety without over-triaging to a medicalized setting or under-triaging to home health, which cannot provide 24/7 supervision.

Key Concept

Indications for post-acute care settings are based on the combination of skilled medical/therapy needs and the requirement for custodial supervision.
Question 4036Question →

A primary care physician is reviewing the electronic health records of four established patients who are scheduled for annual health maintenance visits this morning. Match each patient's specific clinical presentation to the single most appropriate, guideline-concordant screening intervention that should be ordered or performed today.

Click a left item, then click its matching right item

Items

A 42-year-old female with average disease risk. Her most recent cervical cytology with HPV co-testing was performed at age 40 and was negative. She has never undergone breast imaging.
A 67-year-old male with a 35-pack-year smoking history who successfully quit smoking 10 years ago. He underwent a normal screening colonoscopy at age 62 and has no other major medical conditions.
A 23-year-old female who is asymptomatic and reports being sexually active with a new partner. Her last cervical cytology was performed at age 21 and was normal.
A 66-year-old female with documented adequate prior negative cervical cancer screenings. She had a normal screening mammogram at age 65 and a normal colonoscopy at age 60. She has never undergone bone density testing.

Matches

Show answer & explanation

Answer

The 42-year-old female matches with initiating biennial screening mammography. The 67-year-old male former smoker matches with ordering annual low-dose chest CT and a one-time abdominal aortic ultrasound. The 23-year-old sexually active female matches with chlamydia and gonorrhea screening. The 66-year-old female matches with ordering a DEXA scan.
Each patient represents a classic demographic for specific USPSTF Grade A or B recommendations. The 42-year-old needs breast cancer screening (starts at age 40). The 67-year-old male smoker needs lung and AAA screening (based on age and smoking history). The 23-year-old needs STI screening (indicated for sexually active women <25). The 66-year-old female needs osteoporosis screening (starts at age 65 for women).

Step-by-Step Solution

1
Evaluate the 42-year-old female for age-appropriate screenings.
She is due for breast cancer screening.
Current USPSTF guidelines recommend starting biennial screening mammography at age 40 for average-risk women. Her cervical screening is up to date.
2
Evaluate the 67-year-old male former smoker for age and exposure-appropriate screenings.
He is due for both lung cancer and abdominal aortic aneurysm (AAA) screening.
He has a >20 pack-year history and quit <15 years ago, meeting LDCT criteria. He is a male aged 65-75 with a smoking history, meeting AAA ultrasound criteria.
3
Evaluate the 23-year-old sexually active female.
She is due for STI screening.
All sexually active women younger than 25 years require annual screening for chlamydia and gonorrhea. She is not yet due for her next Pap smear.
4
Evaluate the 66-year-old female with up-to-date cancer screenings.
She is due for osteoporosis screening.
Routine screening for osteoporosis with a DEXA scan is recommended for all women aged 65 years and older.

Key Concept

Age, biological sex, and risk factor-based application of USPSTF preventive screening guidelines.
Question 4037Question →

A 3838-year-old male nurse is evaluated during a routine follow-up visit. Six weeks ago, he was diagnosed with latent tuberculosis infection after routine occupational screening revealed a positive interferon-gamma release assay. A chest radiograph at that time was normal. He was started on a daily regimen of isoniazid and pyridoxine. Prior to initiating therapy, his baseline hepatic transaminase levels and bilirubin were within normal limits.

Today, he reports that he feels well, exercises three times a week, and has no fatigue, nausea, vomiting, or abdominal pain. He drinks one glass of wine occasionally but has not consumed any alcohol in the past two weeks. Physical examination shows an anicteric patient with a non-tender abdomen and no hepatomegaly.

Current laboratory studies are as follows:

Laboratory TestResultReference Range
Aspartate aminotransferase (AST)135135 U/L10−4010-40 U/L
Alanine aminotransferase (ALT)165165 U/L7−457-45 U/L
Alkaline phosphatase8888 U/L40−12040-120 U/L
Total bilirubin0.80.8 mg/dL0.1−1.20.1-1.2 mg/dL

Which of the following is the most appropriate next step in the management of this patient's condition?

Show answer & explanation

Answer: Continue the current regimen and repeat laboratory studies in 2 to 4 weeks

Answer

Continue the current regimen and repeat laboratory studies in 2 to 4 weeks
The correct answer is to continue the current regimen and repeat laboratory studies in 22 to 44 weeks. Isoniazid (INH) frequently causes a mild, asymptomatic elevation in hepatic transaminases in up to 10%10\% to 20%20\% of patients. This phenomenon is often transient, and patients can safely continue therapy. According to clinical guidelines, INH should only be discontinued if transaminases rise to greater than 33 times the upper limit of normal (ULN) in the presence of symptoms (e.g., fatigue, nausea, vomiting, abdominal pain), or greater than 55 times the ULN in the absence of symptoms. This patient is completely asymptomatic, and his AST (135135 U/L) and ALT (165165 U/L) are between 33 and 44 times the ULN. Therefore, he does not meet the criteria for stopping the medication. The safest and most appropriate next step is to continue the current treatment and closely monitor his liver function tests to ensure they do not exceed the 55 times ULN threshold.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and laboratory results.
The patient is completely asymptomatic but has elevated AST (135135 U/L) and ALT (165165 U/L).
Identifying the presence or absence of symptoms is critical for applying drug toxicity guidelines.
2
Calculate the degree of transaminase elevation relative to the upper limit of normal (ULN).
AST is approximately 3.43.4 times the ULN (135/40135 / 40). ALT is approximately 3.73.7 times the ULN (165/45165 / 45).
Guidelines for isoniazid hepatotoxicity rely on exact multiples of the ULN to dictate management.
3
Apply the guideline criteria for isoniazid-induced hepatotoxicity.
Isoniazid must be discontinued if transaminases are >3> 3 times the ULN with symptoms, OR >5> 5 times the ULN without symptoms. Because this patient is asymptomatic and his levels are <5< 5 times the ULN, he does not meet criteria for stopping the drug.
Up to 20% of patients on isoniazid develop transient, asymptomatic transaminitis that resolves without discontinuing therapy.
4
Select the appropriate follow-up management.
The patient should continue the medication and have his liver function tests rechecked in 22 to 44 weeks.
Close monitoring ensures that if the transaminitis worsens to >5> 5 times the ULN, the medication can be stopped promptly before fulminant liver failure occurs.

Key Concept

Management of isoniazid-induced hepatotoxicity requires continuing therapy and monitoring if transaminases are less than 5 times the upper limit of normal in asymptomatic patients.
Estimated Time:1m 30s
Question 4038Question →

An asymptomatic 67-year-old woman visits her primary care physician to review her preventive health needs. Her past medical history includes hypertension, diet-controlled type 2 diabetes mellitus, and a total abdominal hysterectomy with bilateral salpingo-oophorectomy performed 12 years ago for cervical intraepithelial neoplasia grade 3 (CIN 3). She takes amlodipine daily.

She has a 54 pack-year smoking history but successfully quit 16 years ago. She consumes a glass of wine on weekends and denies any illicit drug use.

Her records indicate the following recent preventive evaluations:
- Screening colonoscopy at age 61 revealed no polyps.
- Screening mammography 6 months ago was interpreted as normal (BI-RADS 1).
- Dual-energy x-ray absorptiometry scan at age 65 showed a T-score of -1.4 at the lumbar spine and -1.2 at the femoral neck.
- Her most recent vaginal cuff cytology combined with human papillomavirus co-testing was performed 4 years ago and was negative.
- She received the 20-valent pneumococcal conjugate vaccine and a two-dose recombinant zoster vaccine series at age 65. She had her annual influenza vaccination 1 month ago.

Physical examination today is unremarkable. Her blood pressure is 128/78 mmHg, and her body mass index is 26 kg/m².

Which of the following is the most appropriate next step in this patient's preventive care?

Show answer & explanation

Answer: Vaginal cuff cytology and human papillomavirus testing

Answer

Vaginal cuff cytology and human papillomavirus testing
The correct answer is vaginal cuff cytology and human papillomavirus testing. Under normal circumstances, cervical cancer screening is discontinued at age 65 with a history of adequate negative prior screening, or immediately following a total hysterectomy for benign indications. However, this patient underwent a hysterectomy for cervical intraepithelial neoplasia grade 3 (CIN 3). According to current ASCCP consensus guidelines, individuals treated for CIN 2, CIN 3, or adenocarcinoma in situ must undergo continued surveillance for 25 years post-treatment, even if this timeline extends beyond age 65. Acceptable surveillance includes HPV testing or co-testing every 3 years. Because her last co-test was 4 years ago, she is currently due for screening.

Step-by-Step Solution

1
Evaluate the patient's gynecologic history and identify indications for continued screening.
The patient had a hysterectomy for CIN 3 twelve years ago. Standard guidelines require cessation of screening at age 65 or after a total hysterectomy for benign disease, but CIN 2/3 is a strict exception.
Prior high-grade dysplasia carries a long-term risk of vaginal cuff malignancy.
2
Determine the required duration and interval for post-CIN 3 screening.
Guidelines mandate continued screening for 25 years post-treatment. The recommended interval for co-testing is every 3 years. Since her last test was 4 years ago, she is currently overdue.
This establishes vaginal cuff evaluation as the definitively indicated next step.
3
Assess the patient's eligibility for lung cancer screening based on her smoking history.
She is 67, has >20 pack-years, but quit 16 years ago. The USPSTF cutoff for screening cessation is quitting >15 years ago.
This rules out the need for an annual low-dose CT scan.
4
Review the remaining preventive interventions (colonoscopy, bone density, AAA screening).
Colonoscopy is not due for another 4 years. Bone density scan is not due for at least another 1-3 years based on mild osteopenia. AAA screening is strictly for males.
Confirms that all other provided options are not indicated at today's visit.

Key Concept

Patients who have undergone a hysterectomy for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) must continue targeted screening of the vaginal cuff for 25 years post-treatment, superseding the usual age 65 cessation rule.
Question 4039Question →

A 4545-year-old man comes to the clinic for a routine follow-up visit. Four weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a daily regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, along with pyridoxine. He reports feeling much better, with resolution of his initial fever, night sweats, and cough. He specifically denies any abdominal pain, nausea, vomiting, dark urine, or unusual fatigue. He has no history of liver disease and does not consume alcohol. Vital signs are within normal limits. Physical examination shows no scleral icterus, and the abdomen is soft and non-tender with no hepatomegaly.

Laboratory studies show:
TestResultReference Range
Total bilirubin0.90.9 mg/dL0.10.1 - 1.21.2 mg/dL
Aspartate aminotransferase (AST)145145 U/L1010 - 4040 U/L
Alanine aminotransferase (ALT)160160 U/L1010 - 4040 U/L
Alkaline phosphatase9595 U/L4040 - 120120 U/L

Which of the following is the best next step in patient management?

Show answer & explanation

Answer: Continue the current medication regimen and recheck liver function tests in 1 to 2 weeks

Answer

Continue the current medication regimen and recheck liver function tests in 1 to 2 weeks.
The correct approach is to continue the current medication regimen and monitor closely. Isoniazid, rifampin, and pyrazinamide are all known to be hepatotoxic. Mild, asymptomatic elevation of aminotransferases is a common, often transient adverse effect observed during the first few weeks of therapy (occurring in 10%10\% to 20%20\% of patients). Standard guidelines recommend discontinuing hepatotoxic tuberculosis medications only if the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceed 33 times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), OR if they exceed 55 times the ULN in the absence of symptoms. In this vignette, the patient's AST (145145 U/L) and ALT (160160 U/L) are approximately 44 times the ULN. Because he is completely asymptomatic, the threshold to discontinue therapy has not been reached.

Step-by-Step Solution

1
Evaluate the patient's symptoms related to potential hepatotoxicity.
The patient denies abdominal pain, nausea, vomiting, dark urine, or fatigue.
The presence or absence of symptoms determines the threshold for discontinuing hepatotoxic tuberculosis medications.
2
Analyze the laboratory results relative to the reference ranges.
AST is 145145 U/L (roughly 3.63.6 times the upper limit of normal) and ALT is 160160 U/L (44 times the upper limit of normal). Total bilirubin and alkaline phosphatase are normal.
Quantifying the degree of aminotransferase elevation is required to apply standard treatment guidelines.
3
Apply standard management guidelines for drug-induced liver injury in tuberculosis treatment.
Since the patient is asymptomatic and the transaminases are less than 55 times the upper limit of normal, the regimen should be continued with close monitoring.
Mild asymptomatic transaminitis occurs in up to 20% of patients on isoniazid and often resolves spontaneously without requiring treatment interruption.

Key Concept

Management of first-line tuberculosis medication hepatotoxicity requires discontinuing drugs if aminotransferases exceed 3 times the upper limit of normal in symptomatic patients, or 5 times the upper limit in asymptomatic patients.
Estimated Time:1m 15s
Question 4040Question →

A regional hospital plans to expand the use of continuous intravenous insulin infusions to its intermediate care medical wards, a practice that was previously restricted to the intensive care unit. Given the high-risk nature of intravenous insulin, the chief quality officer convenes a multidisciplinary team before the new policy is implemented. The team systematically maps out the proposed new workflow, from the initial physician order to nurse administration and blood glucose monitoring. At each step, they brainstorm how the process might fail, evaluate the potential clinical consequences of such a failure, and calculate a risk priority number. This analysis is then used to design safety constraints prior to the program's official launch. Which of the following best describes the methodology this team is utilizing?

Show answer & explanation

Answer: Failure mode and effects analysis

Answer

The correct answer is Failure mode and effects analysis.
The correct answer is Failure Mode and Effects Analysis (FMEA). FMEA is a proactive, systematic method for evaluating a process to identify where and how it might fail, and to assess the relative impact of different failures. In this scenario, the team is proactively mapping out a new, high-risk workflow (intravenous insulin on an intermediate ward) before implementation. By brainstorming potential failures and calculating a risk priority number (typically based on severity, occurrence probability, and detectability), they are employing the hallmark steps of an FMEA to design safety constraints.

Step-by-Step Solution

1
Identify the temporal relationship of the quality improvement initiative.
The intervention (intravenous insulin on a new ward) has not yet been implemented, making this a prospective approach.
Determining whether an analysis is proactive (before an event) or reactive (after an event) narrows down the appropriate methodologies.
2
Analyze the specific actions being taken by the multidisciplinary committee.
The team is mapping the workflow, identifying potential failures at each step, predicting consequences, and calculating a risk priority number.
These specific steps define the exact quality improvement tool being utilized by the team.
3
Match the identified characteristics with the correct methodology.
A prospective analysis that assigns risk priority numbers to anticipated failures is a Failure Mode and Effects Analysis (FMEA).
This differentiates FMEA from retrospective tools like RCA or iterative testing models like the PDSA cycle.

Key Concept

Failure Mode and Effects Analysis (FMEA) is a prospective, multidisciplinary team approach used to identify and mitigate potential process failures before they cause patient harm.
PreviousPage 202 / 237Next
All practice questions — USMLE Step 3 | Examkin